Monument Therapeutics, a stratified medicine company, today announced Monument Therapeutics the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director. Monument recently raised £2.625 million in seed funding and applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments.
The company has a pipeline of drug development programmes, with the most advanced two being for cognitive impairment in schizophrenia and post-operative cognitive dysfunction (POCD).
Dr Gilbert brings deep expertise in the development and commercialising of repurposed and reprofiled compounds. He was Co-Founder and CEO of Acacia Pharma Group, a hospital pharmaceuticals company. Prior to this, Gilbert was Co-founder and Commercial Director of Arakis, a specialist pharmaceutical repurposing company. He has also worked at Chiroscience, Mundipharma International, BTG and GSK. He is Non-Executive Director of Exvastat and Nuformix and holds a PhD in Pharmaceutics from the University of Nottingham.
Monument Chairman Dr Mark Treherne added: “I’m delighted to welcome Julian to Monument’s board, where his commercial and strategic insights will further strengthen our ability to rapidly develop new treatments based on existing, safe drugs. Repurposing small molecules to treat psychiatric and neurological is an area with huge potential, but few people have Julian’s experience in successfully building companies around this approach.”
